# Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

> **NCT07187804** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Kim's Eye Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Age-related Macular Degeneration (ARMD)
- Choroidal Neovascularization
- Anti-vascular Endothelial Growth Factor

## Interventions

- **DRUG:** Intravitreal faricimab injection

## Key facts

- **NCT ID:** NCT07187804
- **Lead sponsor:** Kim's Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2028-09-22
- **Final completion:** 2028-09-22
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187804, "Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07187804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*